Cytidine, 3'-deoxy-3'-(hydroxymethyl)- | 133713-59-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: Cytidine, 3'-deoxy-3'-(hydroxymethyl)-
• 英文别名: 4-amino-1-[(2R,3R,4S,5S)-3-hydroxy-4,5-bis(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
• CAS: 133713-59-4
• 化学式: C₁₀H₁₅N₃O₅
• 分子量: 257.246
• InChiKey: BOSBLRZAOWVMFK-SQEXRHODSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  129
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• Anti-HCV nucleoside derivatives
  申请人：——

  公开号：US20030008841A1

  公开（公告）日：2003-01-09

  The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.

  本发明涉及新颖和已知的嘌呤和嘧啶核苷衍生物，已发现这些衍生物对丙型肝炎病毒（HCV）具有活性。本发明声明利用这些衍生物治疗HCV感染，以及本文所披露的新颖核苷衍生物。
• [EN] 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV<br/>[FR] NUCLÉOSIDES MÉTHYLE OU ALCYNYLE SUBSTITUÉS EN POSITION 3 POUR LE TRAITEMENT DU VIRUS DE L'HÉPATITE C
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2015161137A1

  公开（公告）日：2015-10-22

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3'-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.

  本文提供了用于治疗黄病毒科感染的化合物、组合物和方法，包括HCV感染。在某些实施例中，披露了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合使用。在某些实施例中，所述化合物是Formula I的3'-取代甲基或炔基核苷衍生物：(I)；或其药学上可接受的盐、溶剂化合物、立体异构体形式、互变异构体形式或多形形式，其中Base、PD、RA、RB1、RB2、RC和Z如本文所定义。
• ANTIVIRAL PHOSPHONATE ANALOGS
  申请人：Boojamra Constantine G.

  公开号：US20090275535A1

  公开（公告）日：2009-11-05

  The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  这项发明涉及具有抗病毒活性的磷取代化合物，包含这种化合物的组合物以及包括给予这种化合物的治疗方法，还包括用于制备这种化合物的过程和中间体。
• 3'-Substituted methyl nucleosides as antiviral agents
  申请人：Bristol-Myers Squibb Company

  公开号：EP0391411A2

  公开（公告）日：1990-10-10

  Certain 3′-substituted methyl nucleosides are disclosed which are useful in the treatment of viral infections, e.g., infections caused by herpes simplex virus types 1 and 2, and/or are useful as intermediates in the preparation of 3′-substituted methyl nucleosides having antiviral activity. In accordance with one aspect of the invention, there are provided novel 3′-substituted methyl nucleosides represented by Formulas I and II wherein: B indicates that B can be either alpha or beta; B is a member selected from the group consisting of the pyrimidine and purine nucleoside bases connected to the tetrahydrofuran ring through the N¹ heterocyclic nitrogen atom of the pyrimidines and the N⁹ or N⁷ heterocyclic nitrogen atom of the purines including the naturally occurring nucleoside bases and 5-fluoro, 5-bromo, 5-iodo, 5-chloro, 5-trifluoromethyl, 5-ethyl, 5-(2-bromovinyl)­uracil; triazolecarboxamide; 2-aminopurine; 2,6-diaminopurine; 4-chloropyrimidine; pyrimidine; azapyrimidine; purine; 2,6-dichloropurine; 2-amino-6-­chloropurine; and deazapurine; R and Q are either both hydrogen or halogen, especially fluorine, or one is hydrogen and the other one is hydroxy or halogen, especially fluorine; in Formula I at least one of R and Q is halogen; and X and Y can be the same or different and are selected from the group consisting of O-alkyl, O-aryl, O-acyl-, halogen, especially fluorine, azido, amino, acylamido, -SH, S-alkyl and S-aryl, or one of X or Y can be hydroxy, or X may be the group R¹O and Y may be the group R²O wherein R¹ and R² are hydrogen or hydroxy-protecting groups. Preferred O-alkyl and S-alkyl groups contain from one to four carbon atoms; preferred O-aryl and S-aryl groups contain from 6 to 10 carbon atoms; and preferred O-acyl groups contain from one to four carbon atoms.

  本发明公开了某些3′-取代的甲基核苷，它们可用于治疗病毒感染，例如由单纯疱疹病毒1型和2型引起的感染，和/或可用作制备具有抗病毒活性的3′-取代的甲基核苷的中间体。根据本发明的一个方面，提供了由式 I 和 II 表示的新型 3′-取代的甲基核苷 其中 B表示B可以是α或β； B 是选自以下组成的组的成员：通过嘧啶的 N¹ 杂环氮原子和嘌呤的 N⁹ 或 N⁷ 杂环氮原子与四氢呋喃环连接的嘧啶和嘌呤核苷碱基，包括天然存在的核苷碱基和 5-氟、5-溴、5-碘、5-氯、5-三氟甲基、5-乙基、5-(2-溴乙烯基)尿嘧啶；三唑甲酰胺； 2-氨基嘌呤； 2,6-二氨基嘌呤；4-氯嘧啶；嘧啶；氮杂嘧啶；嘌呤；2,6-二氯嘌呤；2-氨基-6-氯嘌呤；以及去氮嘌呤； R 和 Q 要么都是氢或卤素，特别是氟，要么一个是氢，另一个是羟基或卤素，特别是氟；在式 I 中，R 和 Q 中至少有一个是卤素；以及 X 和 Y 可以相同或不同，选自由 O-烷基、O-芳基、O-酰基、卤素（尤其是氟）、叠氮、氨基、酰氨基、-SH、S-烷基和 S-芳基组成的组，或者 X 或 Y 中的一个可以是羟基，或者 X 可以是基团 R¹O，Y 可以是基团 R²O，其中 R¹ 和 R² 是氢或羟基保护基团。 优选的 O-烷基和 S-烷基含有 1 至 4 个碳原子；优选的 O-芳基和 S-芳基含有 6 至 10 个碳原子；优选的 O-酰基含有 1 至 4 个碳原子。
• 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
  申请人：IDENIX PHARMACEUTICALS LLC

  公开号：US10202411B2

  公开（公告）日：2019-02-12

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.

  本文提供了用于治疗黄病毒科感染（包括 HCV 感染）的化合物、组合物和方法。在某些实施方案中，公开了核苷衍生物的化合物和组合物，可单独使用或与其他抗病毒药物联合使用。在某些实施方案中，所述化合物为式I的3′-取代甲基或炔基核苷：(I)；或其药学上可接受的盐、溶液剂、立体异构体形式、同分异构体形式或多晶型形式，其中Base、PD、RA、RB1、RB2、RC和Z如本文所定义。